The mesolimbic pathway through the release of dopamine from neurons in the ventral tegmental area (VTA), which project to the nucleus accumbens (NAc), is thought to have a role in motivation and reward processes. Some addictive drugs produce their potent effects on behavior by enhancing mesolimbic dopamine activity. Release of dopamine from VTA neurons is controlled by various factors and neuronal structures. One pathway providing regulatory input to the VTA originates in the mesopontine nuclei of the brainstem. We have previously shown that the mesopontine-VTA-NAc pathway is modulated by the novel neuropeptide urotensin II (Uil). To facilitate our studies we have developed and validated a fusion of diphtheria toxin with UN (Dtx-Uli). This toxin is able to selectively ablate Ull-R expressing neurons of the mesopontine without damage to surrounding tissue. Through the combination ofthis toxin with microdialysis and behavioral paradigms (self-administration and conditioned place preference), we will establish whether Uil can modulate reinforced behaviors. In addition, to better understand the function ofthe mesopontine nuclei, the Dtx-Uli will be used to ablate neurons of this region. Subsequently, different aspects of proposed mesopontine function will be tested ( ex. prepulse inhibition, conditioned place preference). Drug addiction is a multifactorial condition. This heterogeneity is partly due to genetic predisposition. Any gene that is expressed in the neuronal circuitry known to modulate the acquisition and maintenance of addiction could impact the development of an addiction, although that gene may not be the direct target of the drug. Uil is an emerging neuromodulator which may have implications in addiction and the development of addiction. Furthermore, in other work UN has been shown to produce cellular remolding, which may point to a role in neuroplasticity. Therefore, future studies will include the investigation ofthe role of Ull-R in molecular neurobiological changes and the development of addiction.

Public Health Relevance

; The current proposal is relevant in that the novel neuropeptide urotensin II may be a previously unrecognized player in the regulation of motivational processes. The Investigation of which may add another layer of understanding the complex action of psychoactive drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Transition Award (R00)
Project #
3R00DA024754-05S1
Application #
8675360
Study Section
Special Emphasis Panel (NSS)
Program Officer
Sorensen, Roger
Project Start
2011-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$38,445
Indirect Cost
$10,445
Name
State University of New York at Buffalo
Department
Pharmacology
Type
Schools of Medicine
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Mueller, L E; Kausch, M A; Markovic, T et al. (2015) Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine. Behav Brain Res 278:271-9
MacLaren, Duncan A A; Markovic, Tamara; Clark, Stewart D (2014) Assessment of sensorimotor gating following selective lesions of cholinergic pedunculopontine neurons. Eur J Neurosci 40:3526-37
Belaid, Hayat; Adrien, Joƫlle; Laffrat, Elodie et al. (2014) Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion. J Neurosci 34:9124-33
MacLaren, Duncan A A; Santini, Joseph A; Russell, Ashley L et al. (2014) Deficits in motor performance after pedunculopontine lesions in rats--impairment depends on demands of task. Eur J Neurosci 40:3224-36